Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...

Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company ...

Bearish flow noted in Soleno Therapeutics (SLNO) with 4,468 puts trading, or 3x expected. Most active are Apr-25 55 puts and Apr-25 70 calls, ...

Soleno Therapeutics, Inc.’s SLNO share price has surged by 35.80%, which has investors questioning if this is right time to sell.

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) traded down 6.7% during mid-day trading on Tuesday ...

Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline) ...

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to excessive eating. Its approval covers both adult and pediatric patients ...

Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of Vykat for Prader-Willi syndrome, despite initial clinical trial challenges.

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, making it the first treatment available for patients who experience feelings of ...